JPRN-UMIN000008623招募中1 期
Exploratory study of Paclitaxel+Trastuzumab therapy for advanced or recurrent gastric cancer with HER2 positive. - Exploratory study of Paclitaxel+Trastuzumab therapy for advanced or recurrent gastric cancer with HER2 positive.
The Cancer Institute Hospital of JFCR0 个研究点目标入组 36 人开始时间: 2012年8月6日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patient with a previous history of serious drug hypersensitivity. . 2) Patient with infectious diseases associated with a fever of 38.0 degrees C or higher 3) Patient with serious complications (interstitial pneumonia or pulmonary fibrosis, difficult-to-control diabetes, renal failure, hepatic failure, and so on) 4) Patient who has heart disease(CHF, old MI, IHD, arrhythmia, and a valvular disease of the heart) 5) Poorly-controlled hypertension 6) Patient with synchronous double cancer or metachronous double cancer with a disease-free interval of less than five years(In-situ cancer, gastric cancer, mucosal cancer, differentiated adenocarcinoma, and skin cancer judged to be cured by treatment are not considered to be active double cancers.) 7) Women of child-bearing potential (intention), pregnant or lactating women 8) Men desiring to have children 9) Patient judged by the investigator(s) to be inappropriate study participants for any other reason
研究者
相似试验
已完成
1 期
Phase I/II study of Paclitaxel+Trastuzumab therapy in 2nd line treatment for advanced or recurrent gastric cancer with HER2 positive.HER2-positive gastric cancerJPRN-UMIN000011863Osaka Medical College Hospital100
已完成
不适用
A phase II study of paclitaxel plus trastuzumab in patients with pretreated recurrent or metastatic gastric cancer.advanced gastric cancerJPRN-UMIN000006403Toyama Prefectural Central Hospital30
已完成
2 期
Phase II study of trastuzumab and paclitaxel in patients with HER2 positive (IHC 3+, IHC 2+ and FISH +) previously treated advanced or recurrent gastric cancerHER2 positive advanced or recurrent gastric cancerJPRN-UMIN000006223Japanese Foundation for Multidisciplinary Treatment of Cancer35
已完成
1 期
Phase1/2 study of nab-Paclitaxel + trastuzumab therapy in 2nd line treatment for HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab combined with fluoropyrimidine and platinum.HER2-positive gastric cancerJPRN-UMIN000014873Kyoto Prefectural University of Medicine, Gatroenterology and Hepatology23
招募中
2 期
Pilot study of S-1/Paclitaxel/Trastuzumab combination chemotherapy for HER2-positive Stage IV advanced gastric cancer.HER2-positive Stage IV advanced gastric cancerJPRN-UMIN000009565Department of Digestive Surgery, Breast and Thyroid Surgery Graduate School of Medical Science Kagoshima University20